Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer

Abstract

For patients with metastatic renal cell cancer (mRCC) who progressed on vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor therapy, the orally administered mammalian target of rapamycin (mTOR) inhibitor everolimus has been shown to prolong progression free survival. Intriguingly, inhibition of mTOR also promotes expansion of… (More)
DOI: 10.1186/1471-2407-11-505

1 Figure or Table

Topics

  • Presentations referencing similar topics